Mirtazapine | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Mirtazapine
Health Canada Patents

EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

Contact Supplier

SPI Pharma has been solving formulation challenges using superior functional materials.

Contact Supplier

Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Contact Supplier

Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

Contact Supplier

FAMAR CDMO- From early development to commercial manufacturing.

Contact Supplier

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Contact Supplier

Mirtazapine

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

39 API Suppliers, 20 USDMF, 15 CEP/COS, 8 JDMF, 10 EU WC, 10 KDMF, 13 NDC API, 20 Listed Suppliers, $ API Reference Price

39 API Suppliers
20 USDMF
15 CEP/COS
8 JDMF
10 EU WC
10 KDMF
13 NDC API
20 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

INTERMEDIATES

20 Intermediate Suppliers

20 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

443 FDF Dossiers, 72 FDA Orange Book, 244 Europe, 36 Canada, 48 Australia, 20 South Africa, 23 Listed Dossiers

443 FDF Dossiers
72 FDA Orange Book
244 Europe
36 Canada
48 Australia
20 South Africa
23 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 15MG, TABLET;ORAL - 30MG, TABLET;ORAL - 45MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, ORALLY DISINTEGRATING;ORAL - 15MG, TABLET, ORALLY DISINTEGRATING;ORAL - 30MG, TABLET, ORALLY DISINTEGRATING;ORAL - 45MG

TABLET;ORAL - 15MG
TABLET;ORAL - 30MG
TABLET;ORAL - 45MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, ORALLY DISINTEGRATING;ORAL - 15MG
TABLET, ORALLY DISINTEGRATING;ORAL - 30MG
TABLET, ORALLY DISINTEGRATING;ORAL - 45MG

RELATED EXCIPIENT COMPANIES

1 Minakem, 5 Evonik, 4 Rochem International Inc, 20 SPI Pharma, 2 Seqens, 4 DKSH, 8 Faran Shimi Pharmaceutical, 8 Boai NKY Pharmaceuticals Ltd, 1 Chynops Pharma, 6 Gangwal Healthcare, 4 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 1 Pramukh Pharmachem, 1 ACG Worldwide, 8 Actylis, 2 Alcedo Pharmachem, 10 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 29 BASF, 1 Clariant, 12 Corel Pharma Chem, 6 DFE Pharma, 1 Finar, 11 Gangwal Chemicals, 5 Ideal Cures Pvt Ltd, 4 Ingredion Pharma Solutions, 37 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 15 Microlex e.U, 1 Nanjing Bold Chemical, 1 NEWEDGE Overseas, 2 Nomisma Healthcare, 3 Novo Excipients, 4 Pharmatrans-Sanaq, 8 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 23 Roquette, 13 Seppic, 7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 10 Sigachi Industries, 2 The Dow Chemical Company, 2 Ulanqab Kema New Material, 1 Valens Pharmachem, 3 Vasa Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

91 Fillers, Diluents & Binders, 54 Coating Systems & Additives, 39 Direct Compression, 38 Disintegrants & Superdisintegrants, 32 Taste Masking, 30 Granulation, 29 Controlled & Modified Release, 28 Thickeners and Stabilizers, 27 Solubilizers, 23 Chewable & Orodispersible Aids, 20 Lubricants & Glidants, 18 Film Formers & Plasticizers, 18 Co-Processed Excipients, 16 Parenteral, 14 Topical, 7 Emulsifying Agents, 7 API Stability Enhancers, 5 Coloring Agents, 5 Rheology Modifiers, 5 Empty Capsules, 4 Vegetarian Capsules, 4 Surfactant & Foaming Agents

91 Fillers, Diluents & Binders
54 Coating Systems & Additives
39 Direct Compression
38 Disintegrants & Superdisintegrants
32 Taste Masking
30 Granulation
29 Controlled & Modified Release
28 Thickeners and Stabilizers
27 Solubilizers
23 Chewable & Orodispersible Aids
20 Lubricants & Glidants
18 Film Formers & Plasticizers
18 Co-Processed Excipients
16 Parenteral
14 Topical
7 Emulsifying Agents
7 API Stability Enhancers
5 Coloring Agents
5 Rheology Modifiers
5 Empty Capsules
4 Vegetarian Capsules
4 Surfactant & Foaming Agents

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 13 NEWS #PharmaBuzz

1 DATA COMPILATION #PharmaFlow
13 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 226 Finished Drug Prices, 2 Annual Reports

2 US Medicaid Prescriptions
226 Finished Drug Prices
2 Annual Reports

MARKET PLACE

13 APIs, 2 FDF Dossiers

13 APIs
2 FDF Dossiers

PATENTS & EXCLUSIVITIES

3 Health Canada Patents

3 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 4 USP, 7 Others

2 EDQM
4 USP
7 Others

$ API Ref.Price (USD/KG) : 359 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

3 All

01 3Merck Canada Inc.

filter Patent Reset all filters

3 All

01 32386547

filter Product Reset all filters

3 All

01 3Mirtazapine

filter Dosage Reset all filters

3 All

01 3Tablet

filter Exp Date Reset all filters

3 All

01 32020-10-09

Product Main Page

01

Merck Canada Inc.

Mirtazapine

PharmScience R&D

Not Confirmed

Merck Canada Inc.

PharmScience R&D

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2020-10-09

Date Granted : 2010-06-08

Mirtazapine

Brand Name : REMERON RD

Patent Number : 2386547

Filing Date : 2000-10-09

Strength per Unit : 15 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2020-10-09

Date Granted : 2010-06-08

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Merck Canada Inc.

Mirtazapine

PharmScience R&D

Not Confirmed

Merck Canada Inc.

PharmScience R&D

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2020-10-09

Date Granted : 2010-06-08

Mirtazapine

Brand Name : REMERON RD

Patent Number : 2386547

Filing Date : 2000-10-09

Strength per Unit : 30 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2020-10-09

Date Granted : 2010-06-08

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

Merck Canada Inc.

Mirtazapine

PharmScience R&D

Not Confirmed

Merck Canada Inc.

PharmScience R&D

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2020-10-09

Date Granted : 2010-06-08

Mirtazapine

Brand Name : REMERON RD

Patent Number : 2386547

Filing Date : 2000-10-09

Strength per Unit : 45 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2020-10-09

Date Granted : 2010-06-08

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
ASK US!